Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapyMegan M. Tu, Dan Theodorescu, Beth A. Jirón Tamburini et al.|Communications Biology|2020Cited by 170
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapyMegan M. Tu, Dan Theodorescu, Robert T. Jones et al.|Science Advances|2019Cited by 126